Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.700 -0.010 (-0.58%)
Official Closing Price Updated: 8:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,164
Open 1.700
Bid (Size) 1.700 (5)
Ask (Size) 1.710 (12)
Prev. Close 1.710
Today's Range 1.680 - 1.720
52wk Range 1.400 - 3.742
Shares Outstanding 13,625,925
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire

Performance

YTD
-18.7%
-18.7%
1 Month
-2.3%
-2.3%
3 Month
-8.6%
-8.6%
6 Month
-8.1%
-8.1%
1 Year
-48.6%
-48.6%

More News

Read More
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars
Via Stocktwits
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at BIO International Convention 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
Via Benzinga
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
From MAIA Biotechnology
Via Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $1.08 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Private Placement of $2,715,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at Biotech Showcase 2025
From MAIA Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is MAIA Biotechnology, Inc. Common Stock publicly traded?
Yes, MAIA Biotechnology, Inc. Common Stock is publicly traded.
What exchange does MAIA Biotechnology, Inc. Common Stock trade on?
MAIA Biotechnology, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for MAIA Biotechnology, Inc. Common Stock?
The ticker symbol for MAIA Biotechnology, Inc. Common Stock is MAIA on the New York Stock Exchange
What is the current price of MAIA Biotechnology, Inc. Common Stock?
The current price of MAIA Biotechnology, Inc. Common Stock is 1.700
When was MAIA Biotechnology, Inc. Common Stock last traded?
The last trade of MAIA Biotechnology, Inc. Common Stock was at 07/25/25 08:00 PM ET
What is the market capitalization of MAIA Biotechnology, Inc. Common Stock?
The market capitalization of MAIA Biotechnology, Inc. Common Stock is 23.16M
How many shares of MAIA Biotechnology, Inc. Common Stock are outstanding?
MAIA Biotechnology, Inc. Common Stock has 23M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.